Abiopharma

🔍 Leproust Emily M. (Executive)

Company: Twist Bioscience Corp (TWST)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 113,318 shares of Common Stock at $26.66 per share (Direct)
  Date: 2026-08-10 | Code: M | equity_swap_involved: false | shares_owned_after: 932,256.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 113,318 shares of Common Stock at $125.1615 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: false | shares_owned_after: 818,938.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 113,318 shares of Employee Stock Option (right to buy) at $26.66 per share (Derivative)
  Date: 2026-08-10 | Code: M | Expires: 2028-11-18 | equity_swap_involved: false | shares_owned_after: 153,221.00 | transaction_form_type: 4 | Footnotes: F7
• Holds 0 shares of Employee Stock Option (right to buy) at $5.95 per share (Derivative)
  Date: 2026-08-10 | Code: H | Expires: 2025-09-28 | Footnotes: F3
• Holds 0 shares of Employee Stock Option (right to buy) at $23.33 per share (Derivative)
  Date: 2026-08-10 | Code: H | Expires: 2029-10-23 | shares_owned_after: 131,290.00 | Footnotes: F4
• Holds 0 shares of Employee Stock Option (right to buy) at $67.85 per share (Derivative)
  Date: 2026-08-10 | Code: H | Expires: 2030-08-31 | Exercise: 2022-12-19 | shares_owned_after: 64,950.00 | Footnotes: F5
• Holds 0 shares of Employee Stock Option (right to buy) at $8.82 per share (Derivative)
  Date: 2026-08-10 | Code: H | Expires: 2027-09-28 | shares_owned_after: 75,439.00 | Footnotes: F6

Footnotes:

• F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025.
• F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $125.00 to $125.51 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
• F3: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
• F4: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
• F5: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
• F6: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
• F7: 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.